학술논문
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
Document Type
Article
Source
In The Lancet Haematology August 2019 6(8):e398-e408
Subject
Language
ISSN
2352-3026